TNF and rheumatoid arthritis: The recent Oral Rheumatoid Arthritis Trial (ORAL) Surveillance study of RA patients showed that tofacitinib (a JAKi) was associated with a greater risk of cancers and major adverse cardiovascular events (MACE) than tumor necrosis factor inhibitors (TNFis) [12].